“…A strategy that is more commonly being utilized to stabilize peptide-based therapeutics is the synthesis of stable peptidomimetics such as peptoids ( N -substituted glycines) ( Figure 2 ) [ 18 , 19 , 20 ]. Peptoids have shown activity as antibacterial [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ], antifungal [ 29 , 30 , 31 ] and antiparasitic [ 32 , 33 , 34 , 35 ] compounds and most importantly they display increased resistance to protease action compared to α-peptides [ 31 , 36 ]. In particular, peptoids have demonstrated antibacterial properties against a range of clinically relevant Gram negative and Gram positive bacteria, with activities that equal or surpass those achieved by many antimicrobial peptides (AMPs) [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ].…”